Alcon Q2 2026: EPS Beats by 11%, Guidance Raised Despite $402M Charge
Alcon reported Q2 2026 adjusted diluted EPS of $0.84, up 11.2% versus the $0.76 consensus, on net sales of $2.78B, 7.2% higher year over year and slightly above the $2.77B estimate. A $402M pre-tax impairment charge related to discontinuing PowerVision programs drove GAAP EPS to $0.00. Alcon raised full-year 2026 core EPS growth guidance to 12% to 15% constant currency and reiterated sales growth of 5% to 7%.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised full-year 2026 guidance for core diluted EPS growth and core operating margin, despite GAAP EPS being pushed to $0.00 by the impairment charge.
Market read
Guidance raise plus segment growth (Unity equipment, ocular health) is likely to drive re-rating, while tariff assumptions and the impairment headline can create two-sided trading.
What to watch
Tariff impact is modeled at $40M to $90M net of mitigating actions; traders may reprice if actual U.S. import rates or mitigation effectiveness differ from management’s assumptions.
Background
Alcon’s Q2 results include a sizable non-cash impairment tied to discontinuing PowerVision accommodative IOL programs, while adjusted metrics show growth and margin improvement.
Ticker impact
Alcon reported Q2 adjusted diluted EPS of $0.84, beat consensus by 11.2%, and raised full-year 2026 core EPS growth guidance to 12% to 15% constant currency.
Near-term upside bias as traders price in higher core EPS growth, with volatility risk around tariff assumptions and the PowerVision program write-down.
The article discloses both the beat (adjusted EPS, net sales) and an explicit guidance increase for core diluted EPS and operating margin, which are direct valuation inputs.
Market effects
Signals continued demand strength in surgical equipment (Unity platform) and vision care ocular health, supporting sentiment for medtech ophthalmology peers.
Tariff sensitivity is explicitly quantified for U.S. import rates, which may influence broader medtech pricing expectations.
Constant-currency guidance framing highlights FX-neutral growth, relevant for global investors comparing medtech earnings durability.
Counterpoint
The raised guidance may be less durable if the PowerVision accommodative IOL discontinuation reflects deeper execution or clinical risk that could reappear elsewhere.
Key entities
- companyAlcon
Reported Q2 adjusted diluted EPS beat and raised full-year 2026 core EPS and operating margin guidance; disclosed a $402M pre-tax impairment tied to PowerVision IOL discontinuation.
